PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-51.02%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-46.54%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-9.60%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-55.20%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
80.95%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
81.13%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
81.13%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.19%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.19%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-3.21%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
316.99%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
184.15%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-28.67%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-39.49%
Negative 5Y CAGR while AVGO stands at 122.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-62.42%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
64.38%
5Y OCF/share CAGR at 75-90% of AVGO's 73.80%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
39.55%
3Y OCF/share CAGR 1.25-1.5x AVGO's 34.25%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
-185.06%
Negative 10Y net income/share CAGR while AVGO is at 691.11%. Joel Greenblatt sees a major red flag in long-term profit erosion.
70.38%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-115.93%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
91.70%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
88.43%
5Y equity/share CAGR at 50-75% of AVGO's 147.32%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
33.93%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
1.01%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
19.89%
Below 50% of AVGO's 71.80%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
42.45%
3Y dividend/share CAGR 1.25-1.5x AVGO's 38.29%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
-17.25%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-29.91%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.06%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-0.62%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
6.74%
Debt growth far above AVGO's 1.06%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-55.80%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-10.69%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.